A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

NCT02692716 · Completed

Last updated 2026-05-28

This clinical trial tested the cardiovascular safety of an oral diabetes medication called semaglutide in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 3,183 people

Who can join Ages 50+ · all sexes

Timeline Started 2017-01 · est. completion 2018-09

Where 228 sites · Algeria, Argentina, Brazil, Canada, Denmark, Germany, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Romania, South Africa, Spain, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT02692716 ↗

Description as written by the study sponsor.

This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.

Treatments tested

semaglutide Drug

For oral use once daily.
placebo Drug

For oral use once daily.

Main thing measured	Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02692716 ↗